One of these convicted fraudsters, Mihir Taneja, pleaded guilty on November 30, 2020, to introduction of misbranded drugs into interstate commerce with the intent to defraud and mislead. He was sentenced to 10 months in prison followed by one year of supervised release and was ordered to pay almost $21 million
The letter emphasized several key points: Bulk compounding of semaglutide and tirzepatide is no longer permitted because FDA removed these products from the national shortage list Marketing terms such as generic Ozempic, semaglutide pills or vitamin-enhanced GLP-1 injections may violate state consumer-protection law when referring to non-approved formulations Misleading advertising of unapproved GLP-1 products falls under the Connecticut Unfair Trade Practices Act (CUTPA) Although the letter did not accuse any specific provider of wrongdoing, Connecticut placed clinics on formal notice that the GLP-1 market was under review and that enforcement would follow if risky practices continued
View in: PubMed Mentions: 17 Fields: Translation:Humans Sugar-sweetened beverages, serum uric acid, and blood pressure in adolescents
SPEARS: So October hits
The scale almost demonstrated convergent validity, with a positive association with a staff measure of patient safety
The accumulation of acylcarnitines in the myocardium is thought to be responsible for impaired myocardial regeneration after myocardial infarction
